Shenzhen Lifotronic Technology Co (688389) - Total Liabilities

Latest as of September 2025: CN¥549.45 Million CNY ≈ $80.40 Million USD

Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has total liabilities worth CN¥549.45 Million CNY (≈ $80.40 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shenzhen Lifotronic Technology Co (688389) cash conversion ratio to assess how effectively this company generates cash.

Shenzhen Lifotronic Technology Co - Total Liabilities Trend (2016–2024)

This chart illustrates how Shenzhen Lifotronic Technology Co's total liabilities have evolved over time, based on quarterly financial data. Check 688389 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Shenzhen Lifotronic Technology Co Competitors by Total Liabilities

The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their total liabilities.

Company Country Total Liabilities
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
China CN¥865.89 Million
Baticim Bati Anadolu Cimento Sanayi AS
IS:BTCIM
Turkey TL10.45 Billion
Farmers National Banc Corp
NASDAQ:FMNB
USA $4.76 Billion
Glencore PLC
LSE:GLEN
UK GBX99.39 Billion
Jilin Expressway Co Ltd
SHG:601518
China CN¥414.27 Million
Dalian Demaishi Precision Technology Co.Ltd
SHE:301007
China CN¥362.01 Million
Bowhead Specialty Holdings Inc.
NYSE:BOW
USA $1.66 Billion
Hubei Radio and Television Information Network Co Ltd
SHE:000665
China CN¥5.92 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Shenzhen Lifotronic Technology Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shenzhen Lifotronic Technology Co market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.26 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shenzhen Lifotronic Technology Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shenzhen Lifotronic Technology Co (2016–2024)

The table below shows the annual total liabilities of Shenzhen Lifotronic Technology Co from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥845.13 Million
≈ $123.67 Million
+58.34%
2023-12-31 CN¥533.76 Million
≈ $78.11 Million
+41.57%
2022-12-31 CN¥377.02 Million
≈ $55.17 Million
+74.14%
2021-12-31 CN¥216.50 Million
≈ $31.68 Million
+48.31%
2020-12-31 CN¥145.98 Million
≈ $21.36 Million
+12.91%
2019-12-31 CN¥129.29 Million
≈ $18.92 Million
-9.92%
2018-12-31 CN¥143.53 Million
≈ $21.00 Million
+16.56%
2017-12-31 CN¥123.15 Million
≈ $18.02 Million
-2.80%
2016-12-31 CN¥126.69 Million
≈ $18.54 Million
--

About Shenzhen Lifotronic Technology Co

SHG:688389 China Medical Devices
Market Cap
$810.72 Million
CN¥5.54 Billion CNY
Market Cap Rank
#10151 Global
#2899 in China
Share Price
CN¥12.93
Change (1 day)
-0.92%
52-Week Range
CN¥12.16 - CN¥14.74
All Time High
CN¥37.22
About

Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more